Hydrea and Zantac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Hydrea (hydroxyurea) and Zantac (ranitidine hydrochloride). Common drug interactions include arthritis among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Hydrea and Zantac. It is created by eHealthMe based on reports of 81 people who take the same drugs from the FDA, and is updated regularly.

What is Hydrea?

Hydrea has active ingredients of hydroxyurea. It is often used in polycythemia vera. eHealthMe is studying from 9,083 Hydrea users. Check the latest studies of Hydrea.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.

On Jul, 29, 2026

81 people who take Hydrea and Zantac together, and have interactions are studied.

What are the common drug interactions of Hydrea and Zantac, by gender? *:

female:

Arthritis (form of joint disorder that involves inflammation of one or more joints)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Back pain
Balance disorder
Blindness
Blood pressure decreased
Blood sodium decreased
Blood stem cell transplant failure
Bradycardia (abnormally slow heart action)
Cellulitis (infection under the skin)

male:

Anaemia (lack of blood)
Death
Skin cancer
Skin lesion
White blood cell count decreased
Abdominal distension
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Asthenia (weakness)
Back disorder
Blood alkaline phosphatase increased

What are the common drug interactions of Hydrea and Zantac, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Enterococcal sepsis
Hyperbilirubinaemia (excess of bilirubin in the blood)
Liver disorder (liver diseases)
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
Accidental exposure

10-19:

Cough
Haemoglobin decreased
Pyrexia (fever)
Respiratory tract congestion (blockage on respiratory system)
Rhinorrhoea (watery mucus discharge from the nose)

20-29:

n/a

30-39:

Blood sodium decreased
Inappropriate adh secretion
Pneumonia
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)

40-49:

Red blood cell count decreased
Serum ferritin increased
Antinuclear factor positive
Aphasia (damage to the parts of the brain that control language)
Balance disorder
Blindness
Blood potassium increased
Cervical vertebral fracture
Conjunctival haemorrhage (bleeding underneath the conjunctiva)
Dysgeusia (disorder of the sense of taste)

50-59:

n/a

60+:

Anaemia (lack of blood)
Renal failure (kidney dysfunction)
Rash pruritic (redness with itching)
Urinary bladder haemorrhage (urinary bladder bleeding)
Death
Chest pain
Cough
Diplopia (double vision)
Dyspnoea (difficult or laboured respiration)
Exanthem (rashes on skin by viral infection)

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 19 people, 23.46%
Primary Myelofibrosis (primary disorder of the bone marrow): 14 people, 17.28%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 12 people, 14.81%
High Blood Pressure: 9 people, 11.11%
Pain: 8 people, 9.88%
Indigestion: 8 people, 9.88%
Gastritis (inflammation of stomach): 7 people, 8.64%
Oedema Peripheral (superficial swelling): 6 people, 7.41%
Diabetes: 6 people, 7.41%
Hypersensitivity: 5 people, 6.17%

* Approximation only. Some reports may have incomplete information.

Do you take Hydrea and Zantac?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously